Flying debris from devastating Joplin tornado causes deadly 'zygomycosis ...
This has caused them to contract a fungal infection known as 'zygomycosis', which is rare but serious and in some cases deadly. Joplin infectious diseases physician Uwe Schmidt said he knows of at least nine patients who have had the infection since ...
Daily Mail - Fri, 10 Jun 2011 08:34

Aggressive Fungal Infection Striking Joplin Victims
ABC News - Fri, 10 Jun 2011 11:31

Potentially fatal infection strikes Joplin tornado victims
Telegraph.co.uk - Thu, 09 Jun 2011 17:42

Rare Fungal Disease the Latest Horrible Thing to Hit Joplin
Riverfront Times (blog) - Fri, 10 Jun 2011 10:50

Rare, Aggressive Fungus Strikes Joplin Tornado Victims
KMOX.com - Fri, 10 Jun 2011 02:12



Crowdsourcing research for diseases
There are more than 10,000 diseases on the planet, asthma to zygomycosis. Geoffrey Siwo wants to cure all of them. And the 35-year-old computational biologist believes he can. Or, rather, that we can, if we can disrupt drug discovery. It's worth ...
USA TODAY - Thu, 02 Oct 2014 07:03

Basilea's partner Astellas receives notification from U.S. FDA of acceptance ...
Mucormycosis (also known as zygomycosis) is an often lethal fungal infection caused by certain emerging molds. Mucormycosis is associated with high morbidity and mortality rates in immunocompromised patients such as patients undergoing chemotherapy ...
GlobeNewswire (press release) - Sat, 06 Sep 2014 05:24

Astellas Receives Notification from FDA of Acceptance of Filing of ...
PR Newswire (press release) - Sat, 06 Sep 2014 05:00

Basilea To Receive Milestone Payment From Astellas - Quick Facts
RTT News - Sat, 06 Sep 2014 05:40



Geoffrey Siwo: Crowdsourcing Cures
There are more than 10,000 diseases on the planet, asthma to zygomycosis. Geoffrey Siwo wants to cure all of them. And the 36-year-old computational biologist believes he can. Or, rather, that we can, if we can disrupt drug discovery. It's worth ...
OZY - Mon, 29 Sep 2014 23:40

Basilea reports that isavuconazole receives orphan drug designations in Europe ...
Mucormycosis (also known as zygomycosis) is an often lethal fungal infection caused by certain emerging molds. Invasive mucormycosis is associated with high morbidity and mortality rates in immunocompromised patients such as patients undergoing ...
GlobeNewswire (press release) - Sun, 13 Jul 2014 22:21

European Medicines Agency accepts Basilea's isavuconazole Marketing ...
Mucormycosis (also known as zygomycosis) is an often lethal fungal infection caused by certain emerging molds. Mucormycosis is associated with high morbidity and mortality rates in immunocompromised patients such as patients undergoing chemotherapy ...
GlobeNewswire (press release) - Wed, 20 Aug 2014 22:24

Astellas New Data on Cresemba for Invasive Mucormycosis
Astellas Pharma, Inc. (ALPMY) announced the presentation of new data on Cresemba (isavuconazole) from an open-label, multi-center phase III study (VITAL) for invasive mucormycosis (also known as zygomycosis) in immunocompromised patients.
Zacks.com - Thu, 09 Oct 2014 13:41

Astellas' New Data on Cresemba for Invasive Mucormycosis - Analyst Blog
NASDAQ - Thu, 09 Oct 2014 15:19

Astellas submits NDA for isavuconazole to treat deadly fungal infections
Isavuconazole has been developed for the treatment of invasive aspergillosis and invasive mucormcosis (also known as zygomycosis), which are life-threatening fungal infections that generally occur in immunocompromised patients. Last year Astellas ...
The Pharma Letter - Thu, 10 Jul 2014 04:03

Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of ...
GlobeNewswire (press release) - Wed, 09 Jul 2014 09:17

Astellas Submits NDA for Life-Threatening Fungal Infection Drug
Drug Discovery & Development - Thu, 10 Jul 2014 06:04

Astellas Submits U.S. New Drug Application for Isavuconazole for the Treatment ...
PR Newswire (press release) - Wed, 09 Jul 2014 08:56


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014